Table 2. Results of univariate and multivariate analysis for overall survival.
|
Results of univariate analyses for all prespecified prognostic factors with 6-months landmark | ||||
|---|---|---|---|---|
| Characteristic | Value | P value of univariate analyses | Median OS in months | 95% confidence interval |
| Initial tumour remission |
100–60% 59–30% 29–0% 0–20% gain; >20% gain |
<0.001 |
77.4 vs 33.5 vs 26.9 vs 29.9 vs14.3 |
30.60–124.18 and 24.78–42.16 and 20.0–33.71 and 27.88–32.06 and 8.56–20.04 |
| Histology |
Non-clear cell vs clear cell histologies |
<0.001 |
13 vs 30.3 |
9.86–16.10 and 26.70–34.04 |
| Heng Score |
Good vs intermediate vs poor |
<0.001 |
29.1 vs 26.9 vs 10.5 |
21.10–37.02 and 14.53–39.19 and 7.50–13.49 |
| Bone metastases |
Pts. with vs without bone metastases |
0.013 |
22.9 vs 31.9 |
14.36–31.54 and 23.84–40.14 |
| MSKCC score |
Good vs intermediate vs poor |
0.065 |
38.7 vs 23 vs 30 |
30.10–47.27 and 14.11–31.79 and 0 to 61.41 |
| ECOG performance status |
ECOG 0 vs ECOG 1 |
0.117 |
30.4 vs 23.9 |
25.24–35.46 and 17.60–30.15 |
| Previous cytokine therapy |
Pts. with vs without previous cytokine therapy |
0.219 |
31 vs 23.9 |
28.16–33.84 and 14.20–33.54 |
| Numer of metastatic organ sites |
<3 vs ⩾3 metastatic organ sites |
0.342 |
30.4 vs 28.2 |
21.18–39.52 and 21.30–35.10 |
| Lung metastases |
Pts. with vs without lung metastases |
0.497 |
24.8 vs 33.5 |
17.96–31.68 and 24.75–39.23 |
| Lymphnode metastases |
Pts. with vs without lymph node metastases |
0.991 |
24.8 vs 31.9 |
17.96–31.68 and 24.75–39.23 |
| Liver metastases | Pts. with vs without liver metastases | 0.923 | 36.7 vs 28.2 | 11.35–62.09 and 21.48–34.88 |
Abbreviations: ECOG=Eastern cooperative oncology group; MSKCC=Memorial Sloan-Kettering Cancer Center; OS=overall survival.
Univariate analysis revealed initial tumour shrinkage (P⩽0.001), histology (clear cell differentiation vs non-clear cell) (P⩽0.001), the Heng Score (P⩽0.001) and bone metastases (P=0.013) as prognostic variables.